Pharmaceuticals News and Research

RSS

University Jaume I patents fluorescent sensor

The University Jaume I (UJI) has patented a new fluorescent chemical sensor that is capable of detecting citric acid at low concentrations more rapidly and cheaply than the current optical sensors.

9 Jul 2007

Roche and Alnylam form RNAi therapeutics alliance

Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced today that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics.

9 Jul 2007

Barr to market generic LAMISIL tablets

Barr Pharmaceuticals has announced that Gedeon Richter, Plc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Novartis Pharmaceutical Corporation's LAMISIL (terbinafine hydrochloride) Tablets, 250 mg. The approval follows the expiration of pediatric exclusivity for LAMISIL.

4 Jul 2007

Lung cancer patients taking Tarceva who develop a rash fair better

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug's developer, OSI Pharmaceuticals, Inc.

4 Jul 2007

Alli jokes - great marketing!

GlaxoSmithKline's new diet drug, Alli, hit shelves nationwide last month.

4 Jul 2007

Increase in prescription drug cost sharing associated with lower rates of drug treatment, adherence

A review of previous studies indicates that an increase in prescription drug cost sharing is associated with a decrease in drug spending and use of pharmacies; and for some chronic conditions, higher cost sharing is associated with greater use of expensive medical services, according to an article in the July 4 issue of JAMA: The Journal of the American Medical Association.

4 Jul 2007

Drugs cost more for elderly men than women

Independent research, involving over 3 million Italians, conducted by Henley Management College and the University of Milan has concluded that the prescription costs for men over the age of 65 is significantly higher than it is for women.

4 Jul 2007

AMA sics drug salesmen on doctors charge groups at annual meeting

The big topic at the American Medical Association's annual meeting this summer was not Michael Moore's Sicko but the AMA's sic-ing drug salesmen on doctors by selling its database.

3 Jul 2007

Elimination of Chagas disease by 2010

A new effort to eliminate Chagas disease by 2010 will be launched tomorrow at a WHO meeting of disease experts and partners.

3 Jul 2007

Skin rash actually signifies better outcomes for pancreatic and lung cancer patients

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug's developer, OSI Pharmaceuticals, Inc.

3 Jul 2007

Patient choice and treatment alternatives for arthritis

Patients with osteoarthritis (OA) and rheumatoid arthritis (RA) face different treatment options and determining which ones to try can be confusing.

29 Jun 2007

Trial shows CERVARIX cervical cancer candidate vaccine effective

Results from an interim analysis of a Phase III study show that CERVARIX, the GlaxoSmithKline (GSK) cervical cancer candidate vaccine, provides up to 100 percent protection against advanced precancerous lesions caused by the most common types of human papillomavirus, types 16 and 18.

28 Jun 2007

New approach for tackling allergies

Allergies, like the common cold and asthma, have basically defied the best efforts of modern medicine to cure them.

28 Jun 2007

FDA fast tracks ViroPharma's treatment of hepatitis C

ViroPharma has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for HCV-796 for treatment of hepatitis C virus infection.

28 Jun 2007

CARS microscopy reveals clues to myelin damage

Researchers have discovered that calcium ions could play a crucial role in multiple sclerosis by activating enzymes that degrade the fatty sheath that insulates nerve fibers.

28 Jun 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007

Indian medicinal plant effective in blocking blood-vessel and tumor growth

Researchers at the University of Kentucky have advanced research of a natural product found in an Indian medicinal plant that has shown effectiveness in blocking blood-vessel and tumor growth.

27 Jun 2007

Barr announces tentative approval for generic version of Effexor tablets

Barr Pharmaceuticals, Inc. has announced that its subsidiary PLIVA has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Wyeth Pharmaceuticals Inc.'s Effexor (Venlafaxine Hydrochloride) Tablets, 25mg, 37.5mg, 50mg, 75mg and 100mg.

27 Jun 2007

Mylan receives FDA approval for Ondansetron tablets

Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.

26 Jun 2007